BR112019007982A2 - vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal - Google Patents

vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal

Info

Publication number
BR112019007982A2
BR112019007982A2 BR112019007982A BR112019007982A BR112019007982A2 BR 112019007982 A2 BR112019007982 A2 BR 112019007982A2 BR 112019007982 A BR112019007982 A BR 112019007982A BR 112019007982 A BR112019007982 A BR 112019007982A BR 112019007982 A2 BR112019007982 A2 BR 112019007982A2
Authority
BR
Brazil
Prior art keywords
major
histocompatibility complex
complex molecules
cells restricted
cells
Prior art date
Application number
BR112019007982A
Other languages
English (en)
Inventor
Malouli Daniel
Nelson Jay
Sacha Jonah
Frueh Klaus
PICKER Louis
Hancock Meaghan
Hansen Scott
Original Assignee
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science filed Critical Univ Oregon Health & Science
Publication of BR112019007982A2 publication Critical patent/BR112019007982A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

são divulgados vetores de cmv que carecem de proteínas ul128, ul130, ul146 e ul147 ativas que também podem compreender um ou mais elementos reguladores de microrna (mre) que restringem a expressão do cmv. a imunização com os vetores de cmv divulgados permite a seleção de diferentes respostas de células t cd8+ - células t cd8+ restringidas por mhc-ia, mhc-ii ou por mhc-e.
BR112019007982A 2016-10-18 2017-10-18 vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal BR112019007982A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662409840P 2016-10-18 2016-10-18
PCT/US2017/057106 WO2018075591A1 (en) 2016-10-18 2017-10-18 Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules

Publications (1)

Publication Number Publication Date
BR112019007982A2 true BR112019007982A2 (pt) 2019-07-02

Family

ID=62018862

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019007982A BR112019007982A2 (pt) 2016-10-18 2017-10-18 vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal

Country Status (22)

Country Link
US (2) US10532099B2 (pt)
EP (1) EP3529363A4 (pt)
JP (2) JP2019531745A (pt)
KR (1) KR102604486B1 (pt)
CN (1) CN110036112B (pt)
AU (1) AU2017346788A1 (pt)
BR (1) BR112019007982A2 (pt)
CA (1) CA3040303A1 (pt)
CL (1) CL2019001054A1 (pt)
CO (1) CO2019004102A2 (pt)
CR (1) CR20190205A (pt)
DO (1) DOP2019000086A (pt)
EA (1) EA201990937A1 (pt)
EC (1) ECSP19031754A (pt)
IL (1) IL266011B2 (pt)
MA (1) MA46588A (pt)
MX (1) MX2019004518A (pt)
PE (1) PE20190840A1 (pt)
SG (1) SG11201903340TA (pt)
TN (1) TN2019000124A1 (pt)
UA (1) UA126860C2 (pt)
WO (1) WO2018075591A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2772265T3 (pl) 2010-05-14 2018-07-31 Oregon Health & Science University Rekombinowane wektory hcmv i rhcmv i ich zastosowania
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2014225886B2 (en) 2013-03-05 2020-04-16 Oregon Health & Science University Cytomegalovirus vectors enabling control of T cell targeting
EP3169787A1 (en) 2014-07-16 2017-05-24 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
SG11201706454VA (en) 2015-02-10 2017-09-28 Univ Oregon Health & Science Methods and compositions useful in generating non canonical cd8+ t cell responses
EP3377636A4 (en) 2015-11-20 2019-11-06 Oregon Health & Science University CMV VECTORS WITH MIKRORNA DETECTION ELEMENTS
TN2019000124A1 (en) * 2016-10-18 2020-10-05 Univ Oregon Health & Science Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
US10632186B1 (en) 2019-03-21 2020-04-28 21C Bio Vaccine to pathogenic immune activation cells during infections
AU2020243095A1 (en) 2019-03-21 2021-10-21 21C Bio Vaccine to pathogenic immune activation cells during infections
US11077185B2 (en) 2019-03-21 2021-08-03 21C Bio Vaccine to pathogenic immune activation cells during infections
CN113950334A (zh) * 2019-06-07 2022-01-18 俄勒冈健康与科学大学 乙型肝炎病毒特异性t细胞应答
CN114206385A (zh) * 2019-06-07 2022-03-18 俄勒冈健康与科学大学 肿瘤相关抗原特异性t细胞应答
CR20220093A (es) * 2019-08-20 2022-06-15 Univ Oregon Health & Science Modulación de las respuestas de células t por ul18 del citomegalovirus humano
CA3161826A1 (en) * 2019-12-16 2021-06-24 Klaus Frueh Multi-specific t cell receptors
CA3226699A1 (en) 2021-08-31 2023-03-09 Vir Biotechnology, Inc. Recombinant hcmv vectors and uses thereof
IL310667A (en) 2021-08-31 2024-04-01 Vir Biotechnology Inc Tuberculosis vaccines
WO2024121424A1 (en) 2022-12-09 2024-06-13 Daniel Zagury Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
WO1988010311A1 (en) 1987-06-26 1988-12-29 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene and use thereof
SG49046A1 (en) 1991-07-05 1998-05-18 American Cyanamid Co Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus
WO1995003399A2 (en) 1993-07-19 1995-02-02 Cantab Pharmaceuticals Research Limited Production method for preparation of disabled viruses
ATE334216T1 (de) 1994-04-29 2006-08-15 Pharmacia & Upjohn Co Llc Impstoff gegen felines immunodefizienz-virus
US5846806A (en) 1994-07-29 1998-12-08 American Cyanamid Company Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
JPH11500014A (ja) 1995-02-21 1999-01-06 キャンタブ ファーマシューティカルズ リサーチ リミティド ウイルス調製物、ベクター、免疫原、及びワクチン
EP0820311A4 (en) 1995-04-04 2002-09-25 Cell Genesys Inc TRANSPLANTATION OF GENETICALLY MODIFIED CELLS WITH LOW CLASS I PROTEIN RATES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX ON THEIR SURFACE
EP0966301B1 (en) 1996-07-31 2005-02-09 Ortho-McNeil Pharmaceutical, Inc. Identification of human cytomegalovirus genes involved in down-regulation of mhc class i heavy chain expression
US20030138454A1 (en) 1997-06-09 2003-07-24 Oxxon Pharmaccines, Ltd. Vaccination method
DE19733364A1 (de) 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
WO1999007869A1 (en) 1997-08-05 1999-02-18 University Of Florida Live recombinant vaccine comprising inefficiently or non-replicating virus
US7204990B1 (en) 2000-11-28 2007-04-17 Medimmune Vaccines, Inc. Attenuation of cytomegalovirus virulence
EP1364037A4 (en) 2001-02-02 2005-08-03 Chemocentryx Inc METHODS AND COMPOSITIONS USEFUL IN STIMULATING AN IMMUNE RESPONSE
WO2002066629A2 (en) 2001-02-21 2002-08-29 Gabriele Hahn Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates
GB0122232D0 (en) 2001-09-14 2001-11-07 Medical Res Council Gene expression
BR0212619A (pt) 2001-09-20 2004-08-17 Glaxo Group Ltd Sequência de nucleotìdeo, vetor, proteìna, composição farmacêutica, dispositivo de liberação intradérmica, método para tratar um paciente que sofre de uma doença ou é suscetìvel a ela, uso de uma sequência de nucleotìdeo, e, processo para a produção de um nucleotìdeo
US20030118568A1 (en) 2001-12-18 2003-06-26 Board Of Trustees Of The University Of Arkansas Viral stealth technology to prevent T cell-mediated rejection of xenografts
US20060073123A1 (en) 2002-04-30 2006-04-06 Jie Mi Adenovirus vectors for immunotherapy
DE10232322A1 (de) * 2002-07-16 2004-07-29 Hahn, Gabriele, Dr. Viral kodierte CxC determinieren den Gewebetropismus von HCMV
WO2005012545A2 (en) 2003-07-25 2005-02-10 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors
AU2005285513B2 (en) 2004-05-25 2011-02-24 Oregon Health And Science University SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
EP1602676A1 (en) 2004-06-01 2005-12-07 SOLVAY (Société Anonyme) Catalytic compositions
US20080044384A1 (en) 2004-06-25 2008-02-21 Medlmmune Vaccines, Inc. Recombinant Human Cytomegalovirus And Vaccines Comprising Heterologous Antigens
WO2006125983A1 (en) 2005-05-23 2006-11-30 Oxxon Therapeutics Ltd Compositions for inducing an immune response against hepatitis b
US8765146B2 (en) 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2008112146A2 (en) 2007-03-07 2008-09-18 The Trustees Of The University Of Pennsylvania 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction
BRPI0814060A2 (pt) 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
ME02101B (me) 2007-10-30 2015-10-20 Genentech Inc Pročišćavanje antitijela hromatografijom izmjene katjona
EP2403527A4 (en) 2009-03-06 2012-11-14 Sinai School Medicine LIVELY WEAKED INFLUENZA VIRUS VACCINES WITH MICRORNA REACTION ELEMENTS
CA2759438C (en) * 2009-04-30 2021-03-30 Fondazione Centro San Raffaele Del Monte Tabor Gene vectors and uses thereof for preventing or reducing expression of a nucleotide sequence in a hematopoietic stem or progenitor cell but not in a differentiated cell
CN102892782B (zh) 2009-12-23 2015-01-14 4-抗体股份公司 针对人类巨细胞病毒的结合成员
US20120289760A1 (en) 2010-01-27 2012-11-15 Hill Ann B Cytomegalovirus-based immunogenic preparations
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2011250191A1 (en) 2010-05-05 2012-11-22 Ulrich Koszinowski Vaccine against beta-herpesvirus infection and use thereof
PL2772265T3 (pl) 2010-05-14 2018-07-31 Oregon Health & Science University Rekombinowane wektory hcmv i rhcmv i ich zastosowania
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
US20140227708A1 (en) 2011-09-16 2014-08-14 Oregon Health & Science University Methods and kits used in identifying microrna targets
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
AU2013355368A1 (en) 2012-12-04 2015-05-28 Merck Sharp & Dohme Corp. Conditional replicating viral vectors
AU2014225886B2 (en) 2013-03-05 2020-04-16 Oregon Health & Science University Cytomegalovirus vectors enabling control of T cell targeting
EP3169787A1 (en) 2014-07-16 2017-05-24 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
SG11201706454VA (en) 2015-02-10 2017-09-28 Univ Oregon Health & Science Methods and compositions useful in generating non canonical cd8+ t cell responses
EP3377636A4 (en) 2015-11-20 2019-11-06 Oregon Health & Science University CMV VECTORS WITH MIKRORNA DETECTION ELEMENTS
AU2017280065B2 (en) * 2016-06-22 2021-07-01 International Aids Vaccine Initiative, Inc. Recombinant cytomegalovirus vectors as vaccines for tuberculosis
CA3028002A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
TN2019000124A1 (en) * 2016-10-18 2020-10-05 Univ Oregon Health & Science Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules

Also Published As

Publication number Publication date
TN2019000124A1 (en) 2020-10-05
EP3529363A1 (en) 2019-08-28
MA46588A (fr) 2021-04-14
CN110036112A (zh) 2019-07-19
JP2023002716A (ja) 2023-01-10
US20180133321A1 (en) 2018-05-17
SG11201903340TA (en) 2019-05-30
EA201990937A1 (ru) 2019-09-30
CR20190205A (es) 2020-01-07
US20200237915A1 (en) 2020-07-30
IL266011B1 (en) 2023-11-01
UA126860C2 (uk) 2023-02-15
US11305015B2 (en) 2022-04-19
AU2017346788A8 (en) 2019-05-16
CL2019001054A1 (es) 2019-09-27
IL266011A (en) 2019-06-30
PE20190840A1 (es) 2019-06-17
JP7478794B2 (ja) 2024-05-07
KR102604486B1 (ko) 2023-11-22
CN110036112B (zh) 2024-05-10
ECSP19031754A (es) 2019-05-31
US10532099B2 (en) 2020-01-14
KR20190064624A (ko) 2019-06-10
MX2019004518A (es) 2019-06-17
DOP2019000086A (es) 2019-07-31
IL266011B2 (en) 2024-03-01
EP3529363A4 (en) 2020-05-06
WO2018075591A8 (en) 2019-04-04
WO2018075591A1 (en) 2018-04-26
CA3040303A1 (en) 2018-04-26
AU2017346788A1 (en) 2019-05-02
CO2019004102A2 (es) 2019-07-10
JP2019531745A (ja) 2019-11-07

Similar Documents

Publication Publication Date Title
BR112019007982A2 (pt) vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal
CO2019000395A2 (es) Genes de mini–distrofina optimizados y casetes de expresión y su uso
WO2018128662A3 (en) Large scale optical phased array
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
EA201891619A1 (ru) Химерные белки и способы регулирования экспрессии генов
BR112019012343A2 (pt) anticorpos il-11ra
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
BR112017003718A2 (pt) inibidores macrocíclicos das interações de proteína/proteína de pd-1/pd-l1 e cd80(b7-1)/pd-l1
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
EA201790532A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса
BR112018005876A2 (pt) serviço de telemetria e/ou localização com base em privilégio de dispositivo móvel
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
BR112017005381A2 (pt) composições que compreendem células recombinantes de bacillus e um inseticida.
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
BR112017011582A2 (pt) fibroblasto de embrião de galinha imortalizado, cultura de célula, métodos para preparação de um cef importalizado, para a replicação de um vetor viral aviário e para a preparação de uma vacina, e, vacina.
EP3521919A4 (en) OPTICAL SENSING DEVICE, LIGHT RECEPTOR DEVICE AND OPTICAL DETECTION SYSTEM
BR112017005504A2 (pt) composições que compreendem células recombinantes de bacillus e um inseticida.
EP3271455A4 (en) Generating virus or other antigen-specific t cells from a naive t cell population
DK3548383T3 (da) System og fremgangsmåde til fortøjning af et luftskib, dermed udstyret luftskib og dermed udstyrede modtagestrukturer
DOP2016000220A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.
EP3803420A4 (en) DISTRIBUTED RESOURCE TEST SYSTEM
DK3274710T3 (da) Forbedrede assays til måling af styrken af humane retinale pigmentepitel (rpe)-celler og fotoreceptorprogenitorer
PH12018502291A1 (en) Relative potency assay for viral vector encoding isomerohydrolases
BR112018014940A2 (pt) combinação de herbicida

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122022027039-5 PROTOCOLO 870220123594 EM 29/12/2022 17:01.